查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1614080

耳鼻喉科疾病治疗市场：按治疗类型、疾病类型、最终用户分类 - 全球预测 2025-2030

ENT Disorder Treatment Market by Treatment Type (Device, Drugs), Disorder Type (Ear, Nose, Throat), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年耳鼻喉科疾病治疗市值为253.4亿美元，预计到2024年将达到268.3亿美元，复合年增长率为6.26%，到2030年将达到387.7亿美元。

耳鼻喉科疾病治疗市场包括耳鼻喉疾病的诊断、管理和治疗。由于污染水平上升、吸烟习惯盛行和人口老化，耳鼻喉科疾病的盛行率不断增加，因此该领域至关重要。应用范围从製药到外科手术以及基于设备的治疗，例如助听器和人工电子耳。最终用途范围延伸至医院、耳鼻喉科诊所和居家医疗机构。推动市场成长的主要因素包括技术进步、医疗成本上升以及耳鼻喉疾病早期诊断和治疗意识的提高。用于准确诊断的人工智慧整合、用于远距患者管理的远端医疗以及个人化医疗方法等机会提供了巨大的成长潜力。公司可以透过投资研发、建立策略伙伴关係以及扩展到新兴市场来利用这些优势，而新兴市场对耳鼻喉疾病的认识和治疗基础设施仍在发展中。然而，严格的监管条件、高昂的治疗费用以及专业医疗专业人员短缺等挑战构成了重大障碍。治疗的潜在副作用和欠发达地区缺乏基础设施等限制进一步阻碍了扩张。创新可能集中在非侵入性治疗方案、先进影像技术和生物分解性植入的开发。透过基于应用程式的监测来提高患者的依从性，以及扩大 AR/VR 在耳鼻喉科医疗培训中的使用，也可以刺激成长。市场动态竞争激烈，其特点是存在大型参与者和大量专注于利基创新的新兴企业。了解当地消费者需求、遵守当地法规并利用数位健康解决方案将帮助您应对这个市场的复杂性，优化业务成长策略，并成为全球领导者，提高喉科疾病管理的品质极为重要。

主要市场统计
基准年[2023] 253.4亿美元
预测年份 [2024] 268.3亿美元
预测年份 [2030] 387.7亿美元
复合年增长率（%） 6.26%

市场动态：快速发展的耳鼻喉科治疗市场的关键市场洞察

供需的动态交互作用正在改变耳鼻喉科治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 耳、鼻、喉过敏原的盛行率增加
    • 世界人口老化以及慢性耳鼻喉疾病和听力损失侵入性治疗的需求
    • 数位化耳鼻喉科诊断及家庭耳鼻喉科诊断的普及
  • 市场限制因素
    • 严格耳鼻喉科药品及器材核准相关规定
  • 市场机会
    • 耳鼻喉科疾病诊治技术进展
    • 政府对耳鼻喉科相关疾病的积极努力和财政支持
  • 市场挑战
    • 欠发达地区对耳鼻喉疾病及现有治疗方法的认知不足

波特五力：驾驭耳鼻喉科治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解耳鼻喉科治疗市场的外部影响

外部宏观环境因素在塑造耳鼻喉疾病治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解耳鼻喉科治疗市场的竞争状况

耳鼻喉科疾病治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵耳鼻喉疾病治疗市场供应商的绩效评估

FPNV定位矩阵是评估耳鼻喉科市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了耳鼻喉科市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，耳鼻喉科市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 个体耳、鼻、喉过敏原增加
      • 世界各地的人口正在老化，这增加了对慢性耳鼻喉疾病和听力损失的侵入性治疗的需求。
      • 随着数位化和家庭耳鼻喉科诊断的引入
    • 抑制因素
      • 耳鼻喉科药品及器材核准严格规定
    • 机会
      • 耳鼻喉科疾病诊断与治疗技术的进步
      • 对耳鼻喉科相关疾病的有利政府措施和财政支持
    • 任务
      • 发展中地区对耳鼻喉科疾病及治疗方法缺乏认识
  • 市场区隔分析
    • 治疗类型：利用耳鼻喉仪器及耳鼻喉药治疗严重耳鼻喉疾病
    • 最终使用者：医院和门诊手术中心越来越多地使用耳鼻喉设备来提供高品质的护理，同时提供专业护理。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗类型分類的耳鼻喉疾病治疗市场

  • 装置
    • 人工电子耳
    • 持续正压呼吸装置
    • 助听器
    • 鼻夹板
  • 药物
    • 发炎药
    • 抗生素
    • 抗组织胺药
    • 类固醇

第七章依障碍类型分類的耳鼻喉科疾病治疗市场

  • 耳朵
    • 梅尼尔氏症
    • 外耳炎
    • 中耳炎
    • 外耳真菌病
  • 鼻子
    • 鼻息肉
    • 鼻炎
    • 鼻窦
  • 喉
    • 咽头炎
    • 扁桃腺炎
    • 咽头炎

第八章 耳鼻喉科疾病治疗市场：依最终使用者分类

  • 门诊手术中心
  • 耳鼻喉科门诊
  • 医院
  • 专科诊所

第九章 北美及南美耳鼻喉科市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太耳鼻喉科疾病治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲/中东/非洲耳鼻喉科治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Integra (IART) 透过新的收购交易推动耳鼻喉科业务
    • Fifth Sense 与英国耳鼻喉科宣布建立策略伙伴关係，以改善对嗅觉和味觉障碍患者的护理
    • Oto 和 Lindus Health 启动远端试验，以改善患者获得耳鸣治疗的机会
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • ALK-Abello AS
  • Apikos Pharma
  • AstraZeneca PLC
  • Bayer AG
  • Cipla Limited
  • Covis Pharma BV
  • Dr. Reddy's Laboratories
  • F. Hoffmann-La Roche AG
  • Fennec Pharmaceuticals Inc.
  • GlaxoSmithKline PLC
  • Integra Lifesciences Corporation
  • Integra Lifesciences CorporationAbbVie Inc.
  • Intersect ENT, Inc. by Medtronic PLC
  • Johnson & Johnson Services, Inc.
  • Karl Storz
  • Merck & Co., Inc.
  • Novartis AG
  • Olympus Corporation
  • OptiNose US, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Sensorion SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vitaris Inc.
Product Code: MRR-757B1C9CAFAB

The ENT Disorder Treatment Market was valued at USD 25.34 billion in 2023, expected to reach USD 26.83 billion in 2024, and is projected to grow at a CAGR of 6.26%, to USD 38.77 billion by 2030.

The ENT disorder treatment market encompasses the diagnosis, management, and therapy for conditions affecting the ear, nose, and throat. This sector is vital due to the increasing prevalence of ENT disorders fueled by rising pollution levels, widespread smoking habits, and aging populations. The application scope ranges from pharmaceuticals to surgical interventions and device-based treatments such as hearing aids and cochlear implants. The end-use scope extends to hospitals, specialized ENT clinics, and home care settings. Key factors driving market growth include technological advancements, increased healthcare expenditure, and a growing awareness about early diagnosis and treatment of ENT disorders. Opportunities such as the integration of artificial intelligence for precise diagnostics, telemedicine for remote patient management, and personalized medicine approaches offer significant growth potential. Companies can capitalize on these by investing in R&D, forming strategic partnerships, or expanding into emerging markets where ENT disorder awareness and treatment infrastructure are still developing. However, challenges like stringent regulatory landscapes, high treatment costs, and a shortage of specialized healthcare professionals pose significant hurdles. Limitations such as potential side effects from treatments, and lack of infrastructure in underdeveloped regions, further hinder expansion. For innovation, the focus could be on developing non-invasive treatment options, advanced imaging technologies, and biodegradable implants. Enhancing patient compliance through app-based monitoring and expanding the use of AR/VR for medical training in ENT could also spur growth. Market dynamics are highly competitive, characterized by the presence of major players and numerous start-ups focused on niche innovations. Understanding localized consumer needs, complying with region-specific regulations, and leveraging digital health solutions will be critical in navigating this market's complexities, optimizing strategies for business growth, and enhancing the quality of ENT disorder management globally.

KEY MARKET STATISTICS
Base Year [2023] USD 25.34 billion
Estimated Year [2024] USD 26.83 billion
Forecast Year [2030] USD 38.77 billion
CAGR (%) 6.26%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving ENT Disorder Treatment Market

The ENT Disorder Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • The rising prevalence of ear, nose, and throat allergens among individuals
    • The growing aging population worldwide and the need of invasive care for chronic ENT disorders and hearing loss
    • Owing adoption of digital and home-based ENT diagnosis
  • Market Restraints
    • Strict regulations associated with the approval of ENT drugs and devices
  • Market Opportunities
    • Technological advancements in the diagnostic and treatment procedures of ENT disorder
    • Favorable government initiatives and funding for ENT-related diseases
  • Market Challenges
    • Insufficient awareness about ENT disorders and available treatments in underdeveloped regions

Porter's Five Forces: A Strategic Tool for Navigating the ENT Disorder Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the ENT Disorder Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the ENT Disorder Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the ENT Disorder Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the ENT Disorder Treatment Market

A detailed market share analysis in the ENT Disorder Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the ENT Disorder Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the ENT Disorder Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the ENT Disorder Treatment Market

A strategic analysis of the ENT Disorder Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the ENT Disorder Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., ALK-Abello AS, Apikos Pharma, AstraZeneca PLC, Bayer AG, Cipla Limited, Covis Pharma BV, Dr. Reddy's Laboratories, F. Hoffmann-La Roche AG, Fennec Pharmaceuticals Inc., GlaxoSmithKline PLC, Integra Lifesciences Corporation, Integra Lifesciences CorporationAbbVie Inc., Intersect ENT, Inc. by Medtronic PLC, Johnson & Johnson Services, Inc., Karl Storz, Merck & Co., Inc., Novartis AG, Olympus Corporation, OptiNose US, Inc., Pfizer Inc., Sanofi SA, Sensorion SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vitaris Inc..

Market Segmentation & Coverage

This research report categorizes the ENT Disorder Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Device and Drugs. The Device is further studied across Cochlear Implants, Continuous Positive Airway Pressure Devices, Hearing Aids, and Nasal Splints. The Drugs is further studied across Anti-inflammatory Drugs, Antibiotics, Antihistamines, and Steroids.
  • Based on Disorder Type, market is studied across Ear, Nose, and Throat. The Ear is further studied across Meniere's Disease, Otitis Externa, Otitis Media, and Otomycosis. The Nose is further studied across Nasal Polyps, Rhinitis, and Sinusitis. The Throat is further studied across Pharyngitis, Tonsillitis, and Tonsillopharyngitis.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, ENT Clinics, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. The rising prevalence of ear, nose, and throat allergens among individuals
      • 5.1.1.2. The growing aging population worldwide and the need of invasive care for chronic ENT disorders and hearing loss
      • 5.1.1.3. Owing adoption of digital and home-based ENT diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulations associated with the approval of ENT drugs and devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in the diagnostic and treatment procedures of ENT disorder
      • 5.1.3.2. Favorable government initiatives and funding for ENT-related diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Insufficient awareness about ENT disorders and available treatments in underdeveloped regions
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Utilization of ENT devices and ENT medications to cater severe ENT conditions
    • 5.2.2. End-User: Increasing usage of ENT devices in hospitals & ambulatory surgical centers offering specialized care while delivering high-quality care
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. ENT Disorder Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Device
    • 6.2.1. Cochlear Implants
    • 6.2.2. Continuous Positive Airway Pressure Devices
    • 6.2.3. Hearing Aids
    • 6.2.4. Nasal Splints
  • 6.3. Drugs
    • 6.3.1. Anti-inflammatory Drugs
    • 6.3.2. Antibiotics
    • 6.3.3. Antihistamines
    • 6.3.4. Steroids

7. ENT Disorder Treatment Market, by Disorder Type

  • 7.1. Introduction
  • 7.2. Ear
    • 7.2.1. Meniere's Disease
    • 7.2.2. Otitis Externa
    • 7.2.3. Otitis Media
    • 7.2.4. Otomycosis
  • 7.3. Nose
    • 7.3.1. Nasal Polyps
    • 7.3.2. Rhinitis
    • 7.3.3. Sinusitis
  • 7.4. Throat
    • 7.4.1. Pharyngitis
    • 7.4.2. Tonsillitis
    • 7.4.3. Tonsillopharyngitis

8. ENT Disorder Treatment Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. ENT Clinics
  • 8.4. Hospitals
  • 8.5. Specialty Clinics

9. Americas ENT Disorder Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific ENT Disorder Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa ENT Disorder Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Integra (IART) to Advance ENT Division with New Buyout Deal
    • 12.3.2. Fifth Sense and ENT UK Announce Strategic Partnership to Improve Care for People Affected by Smell and Taste Disorders
    • 12.3.3. Oto and Lindus Health Launch a Remote Trial to Increase Patient Access to Tinnitus Therapy
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. ALK-Abello AS
  • 3. Apikos Pharma
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. Cipla Limited
  • 7. Covis Pharma BV
  • 8. Dr. Reddy's Laboratories
  • 9. F. Hoffmann-La Roche AG
  • 10. Fennec Pharmaceuticals Inc.
  • 11. GlaxoSmithKline PLC
  • 12. Integra Lifesciences Corporation
  • 13. Integra Lifesciences CorporationAbbVie Inc.
  • 14. Intersect ENT, Inc. by Medtronic PLC
  • 15. Johnson & Johnson Services, Inc.
  • 16. Karl Storz
  • 17. Merck & Co., Inc.
  • 18. Novartis AG
  • 19. Olympus Corporation
  • 20. OptiNose US, Inc.
  • 21. Pfizer Inc.
  • 22. Sanofi SA
  • 23. Sensorion SA
  • 24. Sun Pharmaceutical Industries Ltd.
  • 25. Teva Pharmaceutical Industries Ltd.
  • 26. Vitaris Inc.

LIST OF FIGURES

  • FIGURE 1. ENT DISORDER TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ENT DISORDER TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ENT DISORDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ENT DISORDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ENT DISORDER TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ENT DISORDER TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY COCHLEAR IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY CONTINUOUS POSITIVE AIRWAY PRESSURE DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY HEARING AIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY NASAL SPLINTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY STEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY EAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY MENIERE'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY OTITIS EXTERNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY OTITIS MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY OTOMYCOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY NASAL POLYPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY RHINITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY SINUSITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY PHARYNGITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY TONSILLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY TONSILLOPHARYNGITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY ENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 139. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 140. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 147. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 148. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 156. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 163. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 164. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 179. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 180. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 187. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 188. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 195. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 196. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 212. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 213. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 220. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 221. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 228. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 229. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 236. FRANCE ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 237. FRANCE ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 244. GERMANY ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 245. GERMANY ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 252. ISRAEL ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 253. ISRAEL ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 260. ITALY ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 261. ITALY ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 268. NETHERLANDS ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 276. NIGERIA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 277. NIGERIA ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 284. NORWAY ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 285. NORWAY ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 292. POLAND ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 293. POLAND ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 300. QATAR ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 301. QATAR ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 308. RUSSIA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 309. RUSSIA ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 316. SAUDI ARABIA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 324. SOUTH AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 332. SPAIN ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 333. SPAIN ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 334. SWEDEN ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 337. SWEDEN ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 338. SWEDEN ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 340. SWEDEN ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 341. SWEDEN ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 342. SWITZERLAND ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 344. SWITZERLAND ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND ENT DISORDER TREATMENT MARKET SIZE, BY DISORDER TYPE, 2018-2030 (USD MILLION)
  • TABLE 346. SWITZERLAND ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 348. SWITZERLAND ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND ENT DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 350. TURKEY ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 351. TURKEY ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE, 2018-2030 (USD MILLION)
  • TABLE 352. TURKEY ENT DISORDER TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 353. TURKEY ENT DI